Nonalcoholic Steatohepatitis (NASH) Clinical Trial 2017-080WIRB

[LCID Study Number: 2017-080WIRB]

Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis

The purpose of this study is to evaluate the efficacy and safety of Obeticholic Acid in subjects with compensated cirrhosis due to Nonalcoholic Steatohepatitis (NASH).

Disease/Condition: Nonalcoholic Steatohepatitis (NASH)

Department: Transplantation & Hepatobiliary Diseases

Location(s): Lahey Hospital & Medical Center (Burlington)

Primary Contact Email: [email protected]

Protocol #: 2017-080WIRB
Principal Investigator(s): Fredric D. Gordon
Study Coordinator(s): Ali Jaber
Trial Phase: Sponsor Initiated Study Phase 3